Protease inhibition, in vitro antibacterial and IFD/MM-GBSA studies of ciprofloxacin-based acetanilides

PLoS One. 2023 Mar 31;18(3):e0281044. doi: 10.1371/journal.pone.0281044. eCollection 2023.

Abstract

In this study, we have investigated ciprofloxacin-based acetanilides for their in-vitro inhibitory study against gram +ve, -ve bacteria and serine protease activity. The compounds 4e and 4g showed excellent antibacterial activity against Bacillus subtilis with a zone of inhibition (ZI) values of 40 ± 0.9 mm, 37 ± 1.4 mm and with MIC values of 4.0 ± 0.78 mg/mL, 3.0 ± 0.98 mg/ML respectively, while 4a and 4i were found most active against Escherichia coli, with ZI values 38 ± 0.1 mm, 46 ± 1.8 mm and with MIC values of 1.0 ± 0.25 mg/mL, 1.0 ± 0.23 mg/mL respectively. All derivatives (4a-j) significantly inhibited the catalytic activity of serine protease, while 4a exhibited a maximum (100%) inhibitory effect at 96 minutes having 22.50 minutes [Formula: see text], and non-competitive inhibition with 0.1±0.00μM Ki. The IFD/MM-GBSA studies highlighted the binding mode of 4a for protease inhibition and indicated improved binding affinity with -107.62 kcal/mol of ΔGbind.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / pharmacology
  • Bacteria
  • Ciprofloxacin* / chemistry
  • Ciprofloxacin* / pharmacology
  • Endopeptidases
  • Microbial Sensitivity Tests
  • Serine Proteases
  • Structure-Activity Relationship

Substances

  • Ciprofloxacin
  • Anti-Bacterial Agents
  • Endopeptidases
  • Serine Proteases

Grants and funding

The authors are thankful to Higher Education Commission (HEC), Pakistan for financial support (No. 5624/Punjab/NRPU/R&D/HEC/2016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.